---------- Forwarded message ----------


NCCN to Host First Annual Hematologic Malignancies Congress in NYC
Internationally known faculty to share advances in the treatment of blood
cancers.

http://snipurl.com/x6ge

NCCN to Host First Annual Hematologic Malignancies Congress in NYC
Internationally known faculty to share advances in the treatment of blood
cancers.

JENKINTOWN, Pa., September 5, 2006 - The National Comprehensive Cancer
Network (NCCN) will debut a new educational program on September 8: the 1st
Annual NCCN Hematologic Malignancies Congress. The event will be held at the
Crown Plaza Times Square in New York.

Over 100,000 new cases of hematologic malignancies will be diagnosed in 2006
alone. Important new treatment advances for these diseases have been
introduced recently, improving the care available to patients with these
blood cancers. As a result, the NCCN is hosting this full-day meeting
featuring world-renowned experts who will discuss these clinical advances.
These including the integration of the recently FDA approved dasatinib
(Sprycel, Bristol-Myers Squibb) in the treatment of chronic myelogenous
leukemia and new agents such as lenalidomide (Revlimid, Celgene) in the
treatment of multiple myeloma and myelodysplastic syndromes. These changes
are all reflected in the NCCN Clinical Practice Guidelines in Oncology,T the
recognized standard for clinical policy in the oncology community. These
guidelines are updated continually in a consensus-driven process with
explicit review of the evidence by multidisciplinary panels of expert
physicians from NCCN member institutions.

Leaders of these multidisciplinary panels will present important updates to
the NCCN guidelines outlining treatment advances, and include Andrew D.
Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center and Margaret R. O'
Donnell, MD, City of Hope Cancer Center.

There will be a media briefing at 11:30 AM, during the meeting, to discuss
the NCCN Clinical Practice Guidelines on hematologic malignancies. Several
thought leaders from NCCN institutions will focus on the advances that have
been made in treating blood cancers and the options that are now available
for patients coping with these diseases. Response to the program has been
outstanding. The second annual Congress is already planned to be a 2-day
event to be held in September, 2007.

For questions about NCCN or for interview information, please contact Thomas
Mitchell at 215.690.0245 .



--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------

You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---

Reply via email to